Would the same paramaters apply for the SAGEOncotest

Great question—you're doing your homework on the different testing options available to you. Let me break down how SAGEOncotest compares to Nagourney in terms of tissue requirements and what each test actually does.

Key Difference: What Each Test Does

This is important because the tissue requirements depend on what they're actually testing:

Nagourney (Ex Vivo Drug Sensitivity Testing):

• Grows your actual tumor cells in culture
• Tests them against multiple chemotherapy and targeted drugs
• Measures which drugs kill your cancer cells most effectively
• Requires viable, living tumor cells → needs substantial tissue (1+ cubic centimeter)

SAGEOncotest (Genomic + Proteomic Analysis):

• Analyzes your tumor's DNA mutations and protein expression
• Tests for specific biomarkers (BRCA, KRAS variants, PD-L1, MSI, etc.)
• Does NOT require living cells—works with fixed/preserved tissue
• Much less tissue-intensive → standard needle biopsy usually sufficient

Tissue Requirements: SAGEOncotest vs. Nagourney

SAGEOncotest:

• Typical requirement: 50-200 cubic millimeters (0.05-0.2 cubic centimeters)
• Standard CT-guided needle biopsy (2-3 passes) is usually adequate
• Can work with smaller samples because they're analyzing DNA/proteins, not growing cells
• Your 3.2 × 3.0 cm nodule would be MORE than sufficient with standard biopsy

Nagourney:

• Requirement: 1,000+ cubic millimeters (1+ cubic centimeter)
• Needs multiple passes or surgical biopsy to get enough viable tissue
• Requires living cells, so timing and handling are critical

Bottom line: SAGEOncotest is much more achievable with a standard needle biopsy procedure.

What SAGEOncotest Would Actually Tell You

Given your specific situation, here's what would be clinically relevant:

Biomarkers SAGEOncotest Tests (Relevant to You):

1. BRCA1/BRCA2 mutations

   • If positive → opens platinum-based chemotherapy + PARP inhibitor options (olaparib, rucaparib)
   • You haven't had this tested yet (based on your profile)
   • This would be actionable given your progression on current therapy

2. KRAS mutations (specific variants)

   • If you have KRAS G12C or G12V → sotorasib or adagrasib (newer targeted therapies)
   • If other KRAS variants → limited targeted options, but helps prognostication
   • Increasingly important in pancreatic cancer treatment planning

3. MSI/dMMR status

   • You're currently pMMR (proficient mismatch repair)
   • But metastatic sites sometimes differ from primary tumor
   • If lung nodule shows dMMR or MSI-high → immunotherapy becomes an option
   • Worth checking given your progression

4. PD-L1 expression

   • Helps determine immunotherapy eligibility
   • Combined with MSI status, guides checkpoint inhibitor use
   • Relevant for your next treatment decision

5. Other mutations (PALB2, TP53, SMAD4)

   • Prognostic information
   • May guide treatment intensity/approach

Why SAGEOncotest Makes More Sense for You Right Now

Compared to Nagourney, here's why SAGEOncotest is probably the better first move:

| Factor | SAGEOncotest | Nagourney | |--------|--------------|-----------| | Tissue needed | Standard biopsy sufficient | Aggressive biopsy/surgery needed | | Procedure risk | Lower (standard needle biopsy) | Higher (multiple passes or VATS) | | Clinical evidence | NCCN/ASCO recommended biomarkers | Limited pancreatic cancer outcome data | | Insurance coverage | Usually covered | Often not covered | | Turnaround time | 7-10 days typically | 2-3 weeks | | Actionable results | Clear treatment implications | May not change oncologist's recommendations | | Cost | Usually covered by insurance | $3,000-5,000+ out of pocket |

Important: Your Current Health Status Matters

Before ANY biopsy, your oncologist needs to assess:

Your Bleeding Risk (Critical):

• Your hematocrit is 32.7% (mild anemia from treatment)
• You didn't list your platelet count—this is essential before biopsy
• Your AST is elevated at 57 U/L (liver stress from cancer spread and recent abscesses)
• Elevated liver enzymes can affect clotting factors

For standard needle biopsy (SAGEOncotest):

• Bleeding risk is manageable with normal platelets (>100)
• If platelets are low, you might need transfusion before procedure
• Your mild anemia is a consideration but not prohibitive

Ask your oncologist: "What's my current platelet count? Do I need any blood work or transfusion before biopsy?"

What NCCN and ASCO Say About This

According to NCCN Pancreatic Cancer Guidelines, when patients progress on initial therapy:

• Repeat biomarker testing (BRCA, KRAS, MSI, PD-L1) is recommended to identify alternative treatment pathways
• This testing should guide next-line therapy selection

According to ASCO Guidelines, biomarker-driven treatment selection improves outcomes in pancreatic cancer when actionable mutations are found.

SAGEOncotest provides exactly these biomarkers with manageable tissue requirements.

Your Practical Next Steps

Option A (Recommended):

1. Standard CT-guided needle biopsy of your 3.2 × 3.0 cm lung nodule
2. Send tissue for SAGEOncotest (biomarker analysis)
3. Results guide your next treatment decision
4. Procedure risk: Lower, tissue requirement: Easily met

Option B (If you want both):

1. Aggressive needle biopsy (multiple passes) or VATS
2. Send tissue for both SAGEOncotest AND Nagourney
3. Get comprehensive biomarker data + drug sensitivity testing
4. Procedure risk: Higher, but maximum information

Option C (If standard biopsy is insufficient):

1. Start with standard needle biopsy for SAGEOncotest
2. If tissue is inadequate, proceed to VATS for additional tissue
3. Can then do Nagourney if desired
4. Staged approach, lower initial risk

Questions to Ask Your Oncologist

1. "Can we do a standard CT-guided needle biopsy of my lung nodule for SAGEOncotest biomarker testing? What specific biomarkers would change my treatment?"

2. "What's my current platelet count? Do I need transfusion before biopsy?"

3. "If SAGEOncotest shows a BRCA mutation, would you recommend platinum + PARP inhibitor therapy? If it shows KRAS G12C, would you consider sotorasib?"

4. "How soon could we have results, and would that affect our treatment timeline?"

5. "Would you recommend SAGEOncotest, Nagourney, or both? What would each result actually change about my treatment?"

6. "Given my elevated liver enzymes and anemia, what's the safest biopsy approach for me?"

The Bottom Line

Yes, SAGEOncotest requires much less tissue than Nagourney. Your 3.2 × 3.0 cm lung nodule would be more than sufficient with a standard needle biopsy (2-3 passes), which carries lower risk than the aggressive biopsy you'd need for Nagourney.

More importantly: SAGEOncotest tests for biomarkers that NCCN and ASCO recommend for guiding treatment in progressive pancreatic cancer. The results would have clear clinical implications for your next treatment decision.

If you want to pursue tissue testing, SAGEOncotest is probably the smarter first move—lower procedure risk, adequate tissue yield, and actionable